VIVA Biotech Holdings - ESG Rating & Company Profile powered by AI
Alternative companies in the rating industry group for VIVA Biotech Holdings are shown. This dashboard contains a Q&A table for VIVA Biotech Holdings. This ESG score for VIVA Biotech Holdings represents its transparency towards the UN Sustainable Development Goals.
VIVA Biotech Holdings in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.7; made up of an environmental score of 6.0, social score of 6.4 and governance score of 4.8.
5.7
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
541 | Wntresearch AB | 5.8 | High |
541 | Zenotech Laboratories Ltd | 5.8 | High |
579 | VIVA Biotech Holdings | 5.7 | High |
579 | Caplin Point Laboratories Ltd | 5.7 | High |
579 | Biotest AG | 5.7 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does VIVA Biotech Holdings have an accelerator or VC vehicle to help deliver innovation?
Does VIVA Biotech Holdings disclose current and historical energy intensity?
Does VIVA Biotech Holdings report the average age of the workforce?
Does VIVA Biotech Holdings reference operational or capital allocation in relation to climate change?
Does VIVA Biotech Holdings disclose its ethnicity pay gap?
Does VIVA Biotech Holdings disclose cybersecurity risks?
Does VIVA Biotech Holdings offer flexible work?
Does VIVA Biotech Holdings have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does VIVA Biotech Holdings disclose the number of employees in R&D functions?
Does VIVA Biotech Holdings conduct supply chain audits?
Does VIVA Biotech Holdings disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does VIVA Biotech Holdings conduct 360 degree staff reviews?
Does VIVA Biotech Holdings disclose the individual responsible for D&I?
Does VIVA Biotech Holdings disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does VIVA Biotech Holdings disclose current and / or historical scope 2 emissions?
Does VIVA Biotech Holdings disclose water use targets?
Does VIVA Biotech Holdings have careers partnerships with academic institutions?
Did VIVA Biotech Holdings have a product recall in the last two years?
Does VIVA Biotech Holdings disclose incidents of discrimination?
Does VIVA Biotech Holdings allow for Work Councils/Collective Agreements to be formed?
Has VIVA Biotech Holdings issued a profit warning in the past 24 months?
Does VIVA Biotech Holdings disclose parental leave metrics?
Does VIVA Biotech Holdings disclose climate scenario or pathway analysis?
Does VIVA Biotech Holdings disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does VIVA Biotech Holdings disclose the pay ratio of women to men?
Does VIVA Biotech Holdings support suppliers with sustainability related research and development?
Does VIVA Biotech Holdings disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does VIVA Biotech Holdings reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is VIVA Biotech Holdings involved in embryonic stem cell research?
Does VIVA Biotech Holdings disclose GHG and Air Emissions intensity?
Does VIVA Biotech Holdings disclose its waste policy?
Does VIVA Biotech Holdings report according to TCFD requirements?
Does VIVA Biotech Holdings disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does VIVA Biotech Holdings disclose energy use targets?
Does VIVA Biotech Holdings disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does VIVA Biotech Holdings have a policy relating to cyber security?
Have a different question?
Potential Risks for VIVA Biotech Holdings
These potential risks are based on the size, segment and geographies of the company.
Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, include protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody drug research and development services, include antigen preparation, multi-species discovery, monoclonal antibodies, antibodies functional screening and identification, antibody engineering transformation, antibody characteristics, and antibody cell line engineering transformation, as well as offers technology platforms, such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high throughput sequencing, computer-aided drug design, HDX-MS, crystal structure determination of protein, and SPR technology. It also provides cell lines, crystal structures, GPCR proteins, antibodies, and proteins. In addition, the company offers contract development and manufacturing services for small molecule active pharmaceutical ingredients (APIs) and intermediates; and trades in APIs, intermediates, and formulations, as well as equity for service. Further, it provides research service; laboratory rental services; and project management and bidding services, as well as sells compounds. The company was incorporated in 2008 and is headquartered in Shanghai, China.